Idioma:

The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine

Marek, Gerard J ; Martin-Ruiz, Raul ; Abo, Allyson ; Artigas, Francesc

Neuropsychopharmacology (New York, N.Y.), 2005-12, Vol.30 (12), p.2205-2215 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine
Autor: Marek, Gerard J ; Martin-Ruiz, Raul ; Abo, Allyson ; Artigas, Francesc
Assuntos: Animals ; Antidepressants ; Antidepressive Agents, Second-Generation - pharmacology ; Antipsychotics ; Anxiety disorders ; Brain Chemistry - drug effects ; Conditioning, Operant - drug effects ; Dose-Response Relationship, Drug ; Drug dosages ; Drug Synergism ; Extracellular Space - drug effects ; Extracellular Space - metabolism ; Fluorobenzenes - pharmacology ; Fluoxetine - pharmacology ; Hypotheses ; Male ; Mental depression ; Microdialysis ; Piperidines - pharmacology ; Post traumatic stress disorder ; Psychotropic drugs ; Rats ; Rats, Sprague-Dawley ; Receptor, Serotonin, 5-HT2A - drug effects ; Reinforcement Schedule ; Serotonin ; Serotonin Antagonists - pharmacology ; Serotonin Uptake Inhibitors - pharmacology
É parte de: Neuropsychopharmacology (New York, N.Y.), 2005-12, Vol.30 (12), p.2205-2215
Descrição: The addition of low doses of atypical antipsychotic drugs, which saturate 5-HT(2A) receptors, enhances the therapeutic effect of selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) in patients with major depression as well as treatment-refractory obsessive-compulsive disorder. The purpose of the present studies was to test the effects of combined treatment with a low dose of a highly selective 5-HT(2A) receptor antagonist (M100907; formerly MDL 100,907) and low doses of a SSRI using a behavioral screen in rodents (the differential-reinforcement-of low rate 72-s schedule of reinforcement; DRL 72-s) which previously has been shown to be sensitive both to 5-HT(2) antagonists and SSRIs. M100907 has a approximately 100-fold or greater selectivity at 5-HT(2A) receptors vs other 5-HT receptor subtypes, and would not be expected to appreciably occupy non-5-HT(2A) receptors at doses below 100 microg/kg. M100907 increased the reinforcement rate, decreased the response rate, and shifted the inter-response time distributions to the right in a pattern characteristic of antidepressant drugs. In addition, a positive synergistic interaction occurred when testing low doses of the 5-HT(2A) receptor antagonist (6.25-12.5 microg/kg) with clinically relevant doses of the SSRI fluoxetine (2.5-5 mg/kg), which both exerted minimal antidepressant-like effects by themselves. In vivo microdialysis study revealed that a low dose of M100907 (12.5 microg/kg) did not elevate extracellular 5-HT levels in the prefrontal cortex over those observed with fluoxetine alone (5 mg/kg). These results will be discussed in the context that the combined blockade of 5-HT(2A) receptors and serotonin transporters (SERT) may result in greater efficacy in treating neuropsychiatric syndromes than blocking either site alone.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 4 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine

Marek, Gerard J ; Martin-Ruiz, Raul ; Abo, Allyson ; Artigas, Francesc

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.